Imidazoline/guanidinium binding sites and their relation to inhibition of K(ATP) channels in pancreatic B-cells.
To elucidate the beta-cytotropic effect of imidazoline compounds their inhibitory effect on ATP-dependent K+ channels (K(ATP) channels) in pancreatic B-cells was compared with their binding to membranes from insulin-secreting HIT T15 cells. K(ATP) channels in inside-out patches from B-cells were closed with the following rank order of efficacy at 10 microM: guanabenz > phentolamine = alinidine > clonidine > idazoxan > rilmenidine = amiloride. The last four compounds achieved an incomplete inhibition only. In contrast to sulfonylureas, the inhibitory action of imidazolines was not enhanced by ADP. With intact cells the site which mediates inhibition is less easily accessible for protonated compounds, suggesting a location at the inner face of the plasma membrane. Competition binding experiments were performed by masking alpha-adrenoceptors and using [3H]clonidine as ligand. Homologous displacement of [3H]clonidine revealed two distinct binding sites in HIT cell membranes characterized by dissociation constants of 38 nM and 4,911 nM and maximal binding capacities of 118 fmol/mg protein and 18 pmol/mg protein. Generally, ligands for I2 imidazoline receptors were more potent than ligands for I1 imidazoline receptors to displace [3H]clonidine from the high affinity site, which does not fit into the current classification of imidazoline receptors. Binding to the second site had affinities in the micromolar range, similar to the concentrations necessary to inhibit K(ATP) channels in B-cells. However, alinidine and phentolamine inhibited K(ATP) channels already at concentrations at which they displaced [3H]clonidine only from the high affinity site, but not yet from the low affinity site. Since the proportion of the low and high affinity site varied in dependence of the competitor, the imidazoline binding sites in HIT cells may not be independent, but may rather represent two interacting or interconvertible sites both of which may be involved in K(ATP) channel closure.
Rustenbeck
I
I
Institute of Pharmacology and Toxicology, University of Göttingen, Germany.
Herrmann
C
C
Ratzka
P
P
Hasselblatt
A
A
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D001667:Binding, Competitive; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D003000:Clonidine / Q000378:metabolism; D004347:Drug Interactions; D019791:Guanidine / Q000378:metabolism* / Q000494:pharmacology; D007093:Imidazoles / Q000378:metabolism* / Q000494:pharmacology; D054755:Imidazoline Receptors; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology / Q000378:metabolism*; D051379:Mice; D018408:Patch-Clamp Techniques; D010646:Phentolamine / Q000494:pharmacology; D026902:Potassium Channel Blockers; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism; D011955:Receptors, Drug / Q000378:metabolism*
D007093:Imidazoles; D054755:Imidazoline Receptors; D007328:Insulin; D026902:Potassium Channel Blockers; D011942:Receptors, Adrenergic, alpha; D011955:Receptors, Drug; D000255:Adenosine Triphosphate; D019791:Guanidine; D003000:Clonidine; D010646:Phentolamine